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To investigate whether vitamin D, smoking, and anti-Epstein-Barr virus (EBV) antibody con-
centrations predict long-term cognitive status and neuroaxonal injury in multiple sclerosis (MS).
Methods
This study was conducted among 278 patients with clinically isolated syndrome who participated
in the clinical trial BENEFIT (Betaferon/Betaseron in Newly Emerging Multiple Sclerosis for
Initial Treatment) and completed the 11-year assessment (BENEFIT-11). We measured serum
25-hydroxyvitamin-D (25(OH)D), cotinine (smoking biomarker), and anti-Epstein-Barr virus
nuclear antigen 1 (EBNA-1) immunoglobulin G (IgG) at baseline and at months 6, 12, and 24
and examined whether these biomarkers contributed to predict Paced Auditory Serial Addition
Test (PASAT)-3 scores and serum neurofilament light chain (NfL) concentrations at 11 years.
Linear and logistic regression models were adjusted for sex, baseline age, treatment allocation,
steroid treatment, multifocal symptoms, T2 lesions, and body mass index.
Results
Higher vitamin D predicted better, whereas smoking predicted worse cognitive performance. A
50-nmol/L higher mean 25(OH)D in the first 2 years was related to 65% lower odds of poorer
PASAT performance at year 11 (95% confidence intervals [95%CIs]: 0.14–0.89). Standardized
PASAT scores were lower in smokers and heavy smokers than nonsmokers (ptrend = 0.026).
Baseline anti–EBNA-1 IgG levels did not predict cognitive performance (ptrend = 0.88).
Associations with NfL concentrations at year 11 corroborated these findings—a 50-nmol/L
higher mean 25(OH)D in the first 2 years was associated with 20% lower NfL (95% CI: −36%
to 0%), whereas smokers had 20% higher NfL levels than nonsmokers (95% CI: 2%–40%).
Anti–EBNA-1 antibodies were not associated with NfL.
Conclusions
Lower vitamin D and smoking after clinical onset predicted worse long-term cognitive function
and neuronal integrity in patients with MS.
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Cognitive impairment is a common and debilitating symptom
of multiple sclerosis (MS),1 substantially affecting patients’
quality of life.2,3 Cognitive impairment is associated with both
white matter inflammatory lesions and gray matter pathology,
such as cortical lesions and brain atrophy,4,5 and is thus also
a manifestation of neurodegenerative pathology.1 Because
there is no established treatment, the search for modifiable
factors that prevent or slow cognitive decline is especially
important.6–9
Low vitamin D, cigarette smoking, and elevated antibodies
against Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-
1), which are established MS risk factors,10 have also been
associated with a clinically and radiologically more active and
faster progressing disease in some,11–24 although not all,
studies.16,24–30 However, whether these MS risk factors spe-
cifically predict patients’ long-term cognitive status has not
been explored.
We have previously reported that among participants in the
clinical trial BENEFIT (Betaferon/Betaseron in Newly
Emerging Multiple Sclerosis for Initial Treatment), those with
higher vitamin D levels at 1 or 2 years after recruitment had
fewer active lesions and less brain atrophy during 5 years of
follow-up.11 In this study, we extended the follow-up to 11
years and examined whether vitamin D, smoking, and anti–
EBNA-1 antibodies early after the first manifestation of
relapsing-remitting MS contributed to predict long-term cog-
nitive function and neuroaxonal integrity independent of
disease-modifying treatment.
Methods
Study population and design
BENEFIT (clinicaltrials.gov: NCT00185211) was a multicen-
ter double-blind phase 3 clinical trial of early vs delayed treat-
ment with interferon beta-1b (INF β-1b) in 468 patients with
clinically isolated syndrome (CIS), a first clinical episode sug-
gestive of MS. Preplanned, rater-blinded follow-up was 5 years,
later followed by observation up to 8.7 years, and then by
assessment at year 11 to evaluate long-term effects of early
treatment. The current investigation was conducted among the
278 patients who completed the 11-year examination
(BENEFIT-11: NCT01795872). These patients comprise
71.3% of all patients at the sites eligible to participate in
BENEFIT-11 and were comparable at baseline to the originally
randomized trial population (medians, age: 30 vs 30 years, 70%
vs 71% females, Expanded Disability Status Scale [EDSS]
score: 1.50 vs 1.50, T2 lesions: 18 vs 17).31 At year 11 assess-
ment, 61.5% of the 278 enrolled patients were on disease-
modifying treatment, and of these, about 50% were on INF
β-1b,31 about 23%were on other injectables, 15% on oral drugs,
9% on monoclonal antibodies, 5% on immunosuppressants,
and <1% on immunoglobulins.
Standard protocol approvals, registrations,
and patient consents
The Harvard T.H. Chan School of Public Health Institutional
Review Board approved this study, and BENEFIT partic-
ipants provided written informed consent. We used deiden-
tified data.
Serum biomarkers of vitamin D, smoking, and
EBV infection
Biomarkers were measured in serum collected at baseline and
at months 6, 12, and 24 for all exposures, and also at months
54 and 60 and at year 11 for vitamin D. Samples were shipped
to a central German laboratory within 3 days of collection and
stored at −20°C before measurement.
Wemeasured 25-hydroxyvitaminD (25(OH)D), the preferred
biomarker of vitamin D nutrition status,10 using ELISA (Im-
munodiagnostic Systems Inc., Fountain Hills, AZ) in samples
collected within the first 24 months and chemiluminescence
immunoassay (Roche Diagnostics) in later samples. From
blind quality control samples, the average coefficients of vari-
ation (CVs) were 4.4% intra- and 11.7% inter-assay for samples
up to month 24 and 4.0% intra- and 4.9% inter-assay for
samples collected thereafter. 25(OH)D levels varied, as
expected, by season, with strong correlations between season-
synchronous and weak correlation between season-
asynchronous levels11 and were thus adjusted for seasonal
variation, as previously described,32 to estimate long-term av-
erage vitamin D status. Briefly, raw 25(OH)D levels were
regressed on the periodic function sin(2πx/12) + (−cos(2πx/
12), where x is the month of blood collection, within strata by
sex adjusting categorically for age (18–22, 23–27, 28–32,
33–37, 38–42, and >43 years) and assay batch. The residuals
derived from this model (raw minus predicted levels) were
added to the sex-specific mean 25(OH)D levels.
We quantified levels of immunoglobulin G (IgG) against
EBNA-1, a measure of past EBV infection, and against viral
capsid antigen (VCA), a measure of acute infection, if EBNA-
1 antibodies are negative, using ELISA (DiaMedix Corp.,
Miami, FL). CVs were 0.95% intra- and 4.2% inter-assay for
EBNA-1.
Glossary
BMI = body mass index; CI = confidence interval; CIS = clinically isolated syndrome; CV = coefficient of variation; EBV =
Epstein-Barr virus; EBNA-1 = Epstein-Barr virus nuclear antigen 1; EDSS = Expanded Disability Status Scale; IgG =
immunoglobulin G; INF β-1b = interferon beta-1b;MS = multiple sclerosis;NfL = neurofilament light chain;OR = odds ratio;
PASAT = Paced Auditory Serial Addition Test; VCA = viral capsid antigen.
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The nicotine metabolite cotinine, a biomarker of current/
recent tobacco use that correlates with the number of cigarettes
smoked,33 was alsomeasured by ELISA. Smokers typically have
levels >25 ng/mL, whereas nonsmokers have levels <10 ng/
mL.34 CVs were 3.1%–7.2% intra- and 12.7%–13.4% inter-
assay.
Cognitive function and neuronal integrity
Cognitive function was assessed during neurologic examina-
tions (baseline, months 6, 12, 18, 24, 30, 36, 42, 48, 54, and 60,
and year 11) by the Paced Auditory Serial Addition Test
(PASAT) on a scale of 0–60. The test was also administered
twice before baseline (at screening and between screening and
baseline) to minimize practice effects from baseline.35 The test
does not assess all aspects of cognition affected in MS, but is
validated to capture the most common MS-specific cognitive
issues with processing speed, attention, and working memory.6
Using a single-molecule array (Simoa),36 serum neurofilament
light chain (NfL) concentrations were determined at baseline,
year 1, and year 11 at the Laboratory of the University Hospital
Basel, Departments of Neurology and Biomedicine, Switzer-
land. NfL is a sensitive biomarker of neuroaxonal injury,
strongly associated with NfL in CSF.37
Statistical analyses
We conducted statistical analyses in SAS 9 (SAS Institute Inc,
Cary, NC). In the primary analyses, we examined whether
serum concentrations of 25(OH)D, cotinine, and anti–EBNA-
1 IgGs measured within the first 24 months after CIS con-
tributed to predict cognitive performance and neuroaxonal
integrity at year 11. This long lag was meant to minimize re-
verse causality, that is, that the disease course itself affected
exposure status and could induce spurious associations.
To assess cognitive performance, we used linear regressionwith
a standardized (z-) PASAT score at year 11 as the outcome
(mean = 52.5, SD = 9.0, 1 unit on the z-PASAT corresponds to
1 SD) and reported regression coefficients (β) and 95% con-
fidence intervals (CIs). Furthermore, we used logistic re-
gression to estimate the odds of scoring worse/more poorly
defined as a PASAT score at or below themedian (56 points) at
year 11 to optimize statistical power with regard to de-
teriorating but still high-functioning patients in this study
population. We reported odds ratios (ORs) and 95% CIs. The
analyses of 25(OH)D were repeated to examine the change in
the PASAT from month 6 to year 11 as the outcome, by
adjusting the models for the PASAT score at month 6.
To examine the neuroaxonal integrity, the associations of
25(OH)D, cotinine, and anti-EBNA-1 IgG within the first 24
months with NfL concentrations at year 11 were assessed using
linear regression. NfL levels were log transformed to improve
normality. As regression coefficients for NfL reflect changes on
the log scale, they were back transformed to reflect changes on
a multiplicative scale (e.g., an estimate of 1.10 corresponds to
10% increase in NfL) and reported as percent difference in
median NfL in the exposure compared with the reference group.
To quantify vitamin D exposure, all season-adjusted 25(OH)
D levels up to month 24 were averaged, except for baseline
concentration, which may have been influenced by the first
clinical episode.12 In secondary analyses, we examined
whether the results differed for mean 25(OH)D within the
first 60 months. Using several measurements allowed us to
classify with more precision the vitamin D exposure over time,
which is likely to be the relevant exposure. These means were
assessed continuously in 50 nmol/L steps and in quintiles as
in previous BENEFIT investigations.11
With regard to smoking exposure, individuals with baseline
cotinine >25 ng/mLwere compared with those with levels <10
ng/mL. Furthermore, patients consistently >25 ng/mL at
baseline and at months 6, 12, and 24 were classified as smokers
and those <10 ng/mL as nonsmokers. These categories were
also chosen a priori based on previous BENEFIT inves-
tigations.25 In a subanalysis, we further distinguished heavy
smokers who had cotinine levels consistently ≥193 ng/mL
(median among smokers). Smokers and heavy smokers were
compared with nonsmokers. If a measurement was missing for
a specific time point, the last available value was carried forward.
The use of multiple cotinine measurements decreases the risk
of misclassification of smoking status. To further decrease the
risk of misclassification, participants with levels of 10–25 ng/
mL or levels changing from <10 to >25 ng/mL across meas-
urements were kept as a separate group in categorical analyses
(similar to a missing indicator) but were not reported in the
results, as their exposure could not be clearly determined.
Finally, anti–EBNA-1 IgG (baseline and months 6, 12, and
24) and anti–VCA IgG levels (months 6 and 12) were ex-
amined in quartiles derived from the antibody distribution at
each time point, using the bottom quartile as the reference, as
in previous BENEFIT studies.25 For categorical exposures, we
reported the p for trend across categories using the median
within each category as a continuous variable to assess dose-
response relationships.
We adjusted all multivariable models for baseline age in 5-year
groups (18–22, 23–27, 28–32, 33–37, 38–42, and >43 years),
sex, treatment allocation at baseline (INF β-1b or placebo),
steroid treatment during CIS (yes-no), multifocal symptom
onset (yes-no), number of baseline T2-weighted MRI lesions
(2–4, 5–8, and ≥9, categorically), and baseline bodymass index
(BMI) (continuously). We also assessed whether results dif-
fered when adjusting the multivariable models categorically for
the region of trial participation (Canada, Scandinavia, and
Northern or Southern Europe). If an exposure was significantly
associated with the outcome(s), we included it as a covariate in
the models of the other exposures.
Because fatigue and depression can influence cognitive per-
formance,38 we moreover examined whether 25(OH)D, coti-
nine, and anti-EBNA-1 IgG were associated with the PASAT
score at year 11 after further adjusting the primary analyses
both for the total fatigue score on the Fatigue Scale for Motor
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and Cognitive Functions (<43: no fatigue, ≥43–<63: mild/
moderate fatigue, ≥63: severe fatigue)38 and for the depression
score on the Center for Epidemiologic Studies Depression
scale (no, mild, and severe depression) assessed at year 11.39
Fatigue was reported by 54% and depressive symptoms by
31.3% of the patients at year 11.31
Data availability
The datasets analyzed in the current study are not publicly
available because of restricted access, but further information
about the datasets is available from the corresponding author
on reasonable request.
Results
Selected baseline characteristics of the 278 BENEFIT-11
participants according to 25(OH)D, cotinine, and anti–
EBNA-1 levels are shown in table 1. The most notable dif-
ferences were a lower BMI and fewer baseline T2 lesions
among patients with higher 25(OH)D and a higher pro-
portion of males among individuals with higher anti–EBNA-1
titers and smokers. Participants had on average 2.6 relapses
during follow-up (range: 0–15), and 13.8% reported intake of
vitamin D supplements from baseline to year 11. The mean
PASAT score was 52.5 (SD ±9), and the mean NfL concen-
tration was 30 pg/mL (SD ±30.5 pg/mL) at year 11. Neither
NfL at baseline (Spearman, r = −0.10, p = 0.13) nor at year 1
(r = −0.11, p = 0.17) correlated with the PASAT at year 11.
NfL at year 1 (r = 0.42, p < 0.0001) correlated more strongly
with NfL at year 11 than baseline NfL (r = 0.25, p = 0.0002).
Long-term cognitive function
Individuals with higher 25(OH)D during the first years fol-
lowing a CIS were less likely to score below the median in the
PASAT performed at year 11. In analyses using 25(OH)D as
a continuous variable, a 50-nmol/L higher mean level within
the first 24 months after CIS was associated with 65% lower
odds of obtaining a below median PASAT score at year 11 (n
= 219: multivariable OR (ORadj) = 0.35, 95% CI: 0.14–0.89, p
= 0.027). We obtained similar results when adjusting also for
the PASAT at month 6 to assess the association between
25(OH)D levels and PASAT score change from month 6 to
year 11 (ORadj = 0.23, 95% CI: 0.07–0.73, p = 0.013). In
categorical analyses, patients with mean 25(OH)D in the top
quintile within the first 24 months were less likely to score
below the median PASAT score at year 11 compared with
those in the bottom quintile, and there was a statistically
significant inverse trend across the categories (figure;
adjusting also for the PASAT at month 6 to assess the PASAT
score change during follow-up: ORadj = 0.33, 95% CI:
0.10–1.09 comparing the top with the bottom quintile, ptrend
= 0.015). Associations were similar for mean 25(OH)D
within the first 60 months (figure). The results of linear re-
gression analyses were also consistent with better cognitive
function in patients with higher mean 25(OH)D-levels, but
did not reach statistical significance (βadj = 0.20, 95% CI:
−0.27 to 0.68 for a 50-nmol/L increment in mean 25(OH)D
within the first 24 months, βadj = 0.25, 95% CI: −0.19 to 0.69
for the same increment over the first 60 months).
Overall, smoking tended to predict worse long-term cognitive
function, although the associations did not reach statistical
significance in all analyses. The OR for a PASAT score below
the median for baseline cotinine levels >25 ng/mL compared
with <10 ng/mL was 1.64 (95% CI: 0.88–3.06, p = 0.12).
Similar results were obtained using average cotinine levels
over the first 24 months (OR = 1.69, 95% CI: 0.88–3.25, p =
0.12). In linear models, smokers tended to have an up to 0.6
SDs worse long-term cognitive performance corresponding to
clinically meaningful 5.4 points on the PASAT, most pro-
nounced among patients considered heavy smokers (cotinine
consistently >193 ng/mL, median among smokers) (table 2).
Anti–EBNA-1 IgG antibodies (at baseline and at months 6,
12, and 24) and anti–VCA IgG antibodies (at months 6 and
12) were not associated with PASAT scores in any analysis
(table 3).
The multivariable models yielded similar results as the age-
and sex-adjusted analyses. The associations between each
exposure and the PASAT score did not meaningfully change
when we mutually adjusted the multivariable models also for
mean 25(OH)D in the first 24 months (those with smoking
or anti–EBNA-1 IgG as main exposures) and/or smoking
based on cotinine levels over the first 24 months (those with
vitamin D or anti–EBNA-1 IgG as main exposures). Adding
region or fatigue and depression indicators into the models
did also not lead to any relevant differences in the results.
Long-term neuroaxonal integrity
The associations with long-term neuronal integrity corrobo-
rated the main findings regarding long-term cognitive per-
formance. A 50-nmol/L higher mean 25(OH)D level in the
first 24 or 60 months was associated with a 20% lower serum
NfL (95% CI: −35% to −1%), indicating less neuroaxonal loss
at year 11 (table 4). Comparing the top with the bottom
quintile of mean 25(OH)D also yielded moderate inverse
associations (table 4). Furthermore, smoking within the first
24 months from onset was associated with a 20% higher NfL
at year 11 (95% CI: 2%–40%) (table 4). Finally, quartiles of
anti–EBNA-1 IgG indices at any of the assessed time points
were not linked to 11-year NfL concentrations (table 4).
Multivariable estimates were similar to the age and sex–only
adjusted estimates. Additional adjustments for 25(OH)D
and/or cotinine did not change the results.
Discussion
Higher mean 25(OH)D levels after clinical MS onset pre-
dicted a better cognitive function as assessed by the PASAT
and lower NfL levels 11 years into the disease course,
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suggesting that adequate vitamin D levels could contribute to
long-term neuroprotection in individuals with MS. Smokers
tended to have worse long-term cognitive scores on the
PASAT and higher NfL levels than nonsmokers. In contrast,
EBV serology markers did not predict cognitive performance
or NfL concentrations. These results are consistent with the
suggestion that vitamin D supplementation and smoking
cessation early after MS onset might protect long-term cog-
nitive function and central neuroaxonal integrity, in-
dependent of disease-modifying treatment.
Our findings are in line with those of previous studies that
suggested an effect of vitamin D and smoking and no effect of
EBV on the EDSS.11,14,18,25 The EDSS, however, is little sen-
sitive to cognitive impairment,40 which was specifically
addressed in our study. Only preliminary evidence was other-
wise available from 2 small studies, one cross-sectional, in
which smoking was associated with worse cognition in MS,41
and the other longitudinal, but with only 3 months of follow-
up, supporting a beneficial effect of vitamin D on cognitive
function.42 Furthermore, a remarkably high proportion of ever
and persistent smokers was observed in a cohort of patients
with MS with predominant severe cognitive impairment.43
Cognitive function was also not reported in the so far in-
conclusive vitamin D supplementation trials in individuals with
MS.26 The awaited results of several larger, thus better-powered
trials may be more informative,44 although a favorable effect on
progression might only become apparent beyond a typical
2-year trial period.
Our findings on cognitive impairment are substantiated by our
results on neuroaxonal injury providing biomarker evidence of
ongoing pathology in the CNS. Both neuroinflammatory and
neurodegenerative processes can increase NfL levels37 and could
contribute to our results. Cortical lesions and gray matter loss are
more strongly associatedwith cognitive decline thanwhitematter
lesions,4 but ultimately, we cannot evaluate from NfL elevations
onlywhich pathologywas driving the results. Intriguingly, vitamin
D supplementation was associated with decreased NfL levels in
a 2-year randomized clinical trial among untreated patients with
MS.45 In another study, smoking was linked to brain atrophy,19
which is, in turn, related to neuroaxonal injury and cognitive
impairment.5 Our findings add to the evidence that NfL may be
a promising biomarker for clinical MS research.
Vitamin D might have neuroprotective properties or be
a prognostic marker of long-term cognition and neuroaxonal
integrity. The direct or immune-mediated biological mecha-
nisms of long-term neuroprotection can only be hypothesized.
In the short term, vitamin D might contribute to maintaining
immune homeostasis as suggested in a previous study.46
Cognitive reserve modifies the expression of cognitive
Table 1 Baseline characteristics of the 278 BENEFIT-11 participants by quintiles of mean 25(OH)D within the first 24
months,a quartiles of baseline EBNA-1 IgG antibody titer,b and baseline cotinine levelsc
Mean 25(OH)D quintiles, nmol/L Baseline EBNA-1 quartiles Baseline cotinine, ng/mL
1 3 5 1 4 <10 >25
Median 30.2 48.9 73.3 3.9 4.9 2.6 162.6
Range 15.8–35.5 44.3–53.0 65.3–106.9 1.2–4.1 4.7–5.3 1.6–8.8 30.2–323.4
No. (%) 53 (19.8) 54 (20.1) 53 (19.8) 67 (25.2) 66 (24.8) 175 (64.1) 93 (34.1)
Age, median (Q1–3), y 31 (25–39) 29 (24–34) 32 (26–38) 32 (26–37) 30 (25–35) 32 (25–38) 29 (24–34)
Male, % 23.9 44.2 34.0 19.7 39.5 26.8 39.8
INF β-1b treatment, % 52.1 54.3 65.5 59.7 55.6 62.1 53.7
Multifocal onset, % 47.3 49.2 46.2 57.1 44.2 54.4 46.8
Steroid use, % 67.4 74.3 68.7 75.7 62.8 70.9 73.3
T2 lesions,
median (Q1–3)

















PASAT mo6, mean (SD)d 54.6 (6.4) 54.9 (6.1) 55.1 (6.7) 54.1 (7.8) 53.9 (7.7) 54.8 (6.9) 53.4 (7.9)
NfL y1, mean
(SD), pg/mLd
29.5 (21.7) 29.5 (21.4) 25.3 (11.9) 24.2 (10.6) 26.4 (13.4) 26.3 (17.9) 30.7 (25.2)
Abbreviations: 25(OH)D = 25-hydroxyvitamin D; BMI = body mass index; EBNA-1 = Epstein-Barr virus nuclear antigen 1; IgG = immunoglobulin G; INF β-1b =
interferon beta-1b; mo6 = month 6; NfL = neurofilament light chain; PASAT = Paced Auditory Serial Addition Test; Q1–3 = 25th–75th percentile; y1 = year 1.
a Mean 25(OH)D concentration of measurements at months 6, 12, and 24.
b Among EBNA-1 IgG-positive individuals (266 of 277 with a baseline measurement of EBNA-1 IgG).
c Cotinine >25 ng/mL indicative of active smoking and <10 ng/mL of nonsmoking; 5 participants had an equivocal baseline level of 10–25 ng/mL.
d PASAT scores at month 6 and serum NfL concentrations at year 1 across categories of main exposures.
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dysfunction following neurodegeneration,47 and higher vitamin
D could, alternatively, be a marker of a higher cognitive reserve.
Cigarette smoking has also been linked to brain atrophy in the
general population and could be directly neurotoxic,48 leading,
for example, to production of nitric oxide in the CSF, which is
thought to promote neurodegenerative processes.15 An
Table 2 Serum cotinine levels, a biomarker of smoking, and long-term cognitive performance as assessed by the PASAT
11 years after CIS
Cotinine levels, ng/mL No.
z-PASAT score 11 years after CISa
Sex- and age-adjusted β (95% CI)b Multivariable β (95% CI)c
At baselined
<10 140 Ref. Ref.
>25 76 −0.30 (−0.61, 0.02) −0.29 (−0.62, 0.04)
All measurementse
<10 125 Ref. Ref.
>25 70 −0.35 (−0.67, −0.02) −0.33 (−0.67, 0.01)
<10 125 Ref. Ref.
>25 to ≤193 61 −0.30 (−0.65, 0.04) −0.29 (−0.64, 0.07)
>193 9 −0.60 (−1.35, 0.15) −0.59 (−1.35, 0.17)
ptrend
f 0.020 0.026
Abbreviations: CI = confidence interval; CIS = clinically isolated syndrome; PASAT = Paced Auditory Serial Addition Test; β = linear regression coefficient.
a Linear regression of smoking status determined by serum biomarker cotinine on standardized PASAT z-scores (mean of zero, SD of 1) 11 years after CIS.
b Adjusted categorically for baseline age (18–22, 23–27, 28–32, 33–37, 38–42, and >43 years) and sex.
c Apart frombaseline age and sex, also adjusted for treatment allocation at baseline (interferon-beta yes-no),multifocal symptomonset (yes-no), T2-weighted
MRI lesions at baseline (categorically: 2–4, 5–8, and ≥9), body mass index at baseline (continuously), and treatment with steroids during first attack (yes-no).
d A baseline serum cotinine level (missing = 3) of >25 ng/mL indicates active cigarette smoking, and <10 ng/mL indicates nonsmoking.
e Serum cotinine levels at baseline and at months 6, 12, and 24 used to classify nonsmokers (all measures <10 ng/mL), smokers (>25 ng/mL), and heavy
smokers (>193 ng/mL). Last available measurement carried forward for missing levels.
f Probability value for linear trend across the medians within each category.
Figure Odds ratio (OR) and 95% confidence intervals (CIs) of poorer cognitive performance on the PASAT (at or below
amedian score of 56) 11 years after clinically isolated syndrome according to quintiles of mean 25-hydroxyvitamin
D (25(OH)D) within the first 24 and 60 months from symptom onset
ORs are adjusted for baseline age and sex, treatment allo-
cation at baseline (interferon-beta yes-no), multifocal
symptom onset (yes-no), T2-weighted MRI lesions at base-
line (categorically: 2–4, 5–8, and ≥9), body mass index at
baseline (continuously), and treatment with steroids during
first attack (yes-no). PASAT = Paced Auditory Serial Addition
Test.
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indirect effect through acceleration of comorbidities like vas-
cular dementia is another possibility.48 Differences could, to
some extent, already have been present at CIS if smoking
patients had been smoking before CIS, which is likely. It is thus
less informative to examine PASAT changes after baseline with
respect to smoking. Whichever the mechanism, our findings
suggest that vitaminD and smoking are independent predictors
of long-term cognitive performance.
The strengths of our study include the longitudinal design, the
systematic long follow-up of participants across study sites, all
recruited at CIS and receiving standard treatment, and the
availability of repeated measurements of serum biomarkers to
consider exposure changes over time, decrease the risk of
misclassification, and exclude reverse causality as an expla-
nation for our findings. Given that there is no established
treatment of cognitive decline and vitamin D supplementa-
tion is safe even at high doses, supplementation could rou-
tinely be considered among patients with CIS and MS,
especially those with insufficient levels.44 To encourage and
offer patients help to quit smoking remains crucial.
Our study has some limitations. The study population con-
sists of white Caucasians, which limits the generalizability of
Table 3 Odds ratio (OR) and 95% confidence intervals (CIs) of worse long-term cognitive performance on the PASAT 11
years after CIS according to quartiles of anti-EBNA-1 and -VCA antibodiesa
No.
PASAT score ≤56 points (median) 11 years after CIS




1 56 Ref. Ref.
2 55 1.26 (0.58–2.75) 1.27 (0.58–2.79)
3 50 1.33 (0.60–2.97) 1.23 (0.54–2.80)





1 49 Ref. Ref.
2 47 0.83 (0.35–1.94) 0.82 (0.34–1.95)
3 48 0.53 (0.23–1.22) 0.50 (0.21–1.19)





1 49 Ref. Ref.
2 47 0.76 (0.33–1.73) 0.76 (0.32–1.80)
3 51 1.13 (0.49–2.60) 1.07 (0.46–2.53)
4 50 0.87 (0.38–1.99) 0.86 (0.36–2.08)
ptrend 0.92 0.92
Abbreviations: CI = confidence interval; CIS = clinically isolated syndrome; EBNA-1 = Epstein-Barr virus nuclear antigen 1; IgG = immunglobulin G; OR = odds
ratio; PASAT = Paced Auditory Serial Addition Test; VCA = viral capsid antigen.
a Odds of the PASAT score at or below the median (56 points) 11 years after CIS comparing higher quartiles of EBNA-1 and VCA IgG antibody titers to bottom
quartile using logistic regression.
b Adjusted categorically for baseline age (18–22, 23–27, 28–32, 33–37, 38–42, and >43 years) and sex.
c Apart frombaseline age and sex, also adjusted for treatment allocation at baseline (interferon-beta yes-no),multifocal symptomonset (yes-no), T2-weighted
MRI lesions at baseline (categorically: 2–4, 5–8, and ≥9), body mass index at baseline (continuously), and treatment with steroids during first attack (yes-no).
d Probability value for linear trend across the medians within the quartiles.
e1956 Neurology | Volume 94, Number 18 | May 5, 2020 Neurology.org/N
Copyright © 2020 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
Table 4 Serum 25-hydroxyvitamin D (25(OH)D), cotinine, and EBNA-1 antibody levels and long-term neuroaxonal injury
as measured by serum NfL concentrations in patients with CIS
No.
NfL level 11 years after CIS
Sex- and age-adjusted % difference (95% CI)a,b Multivariable adjusted % difference (95% CI)a,c
Mean 25(OH)D levels
First 24 mo
50 nmol/L increments 217 −14% (−31 to +7%) −20% (−36% to 0%)
P 0.19 0.05
Quintile
1 39 Ref. Ref.
2 44 −10% (−28 to +13%) −11% (−29 to +11%)
3 48 −10% (−28 to +12%) −15% (−32 to +7%)
4 46 −8% (−27 to +16%) −13% (−31 to +9%)




50 nmol/L increments 217 −15% (−31 to +5%) −20% (−35% to −1%)
P 0.12 0.04
Quintile
1 40 Ref. Ref.
2 44 −7% (−26 to +17%) −6% (−25 to +18%)
3 45 −5% (−24 to +20%) −8% (−27 to +15%)
4 49 −6% (−25 to +18%) −9% (−27 to +14%)
5 39 −16% (−34 to +6%) −20% (−37% to +1%)
ptrend 0.19 0.073
All cotinine levelse, ng/mL
<10 124 Ref. Ref.
>25 68 +21% (+3 to +41%) +20% (+2 to +40%)
p 0.019 0.025
<10 124 Ref. Ref.
>25 to ≥193 61 +21% (+3 to +43%) +21% (+3 to +43%)





1 53 Ref. Ref.
2 50 −7% (−24 to +14%) −8% (−24 to +12%)
3 54 +22% (−1 to +48%) +21% (−1 to +48%)
4 58 −1% (−18 to +21%) −1% (−18 to +20%)
Continued
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our findings to other racial/ethnic groups. We could not assess
whether even higher vitamin D levels (;100 nmol/L) have an
additional favorable effect on the disease course. Moreover, we
might have underestimated the effect of smoking, as ever-
smokers were misclassified as nonsmokers if they stopped
smoking at or before CIS. Furthermore, we could not adjust
our analyses for education or physical activity. These or other
factors could confound the associations between vitamin D/
smoking and cognitive decline. However, evidence of a bene-
ficial effect of exercise on cognitive performance is preliminary
and could be explained by a favorable impact on mood and/or
fatigue.9,49,50 Moreover, about one-third of the patients were
treated with disease-modifying drugs other than INF β-1b at
year 11; however, we had no information about when they
switched to which treatment during follow-up and could
therefore not adjust the analyses for treatment differences
among the patients. In addition, the PASAT is not an ex-
haustive measure of cognition in MS, and the use of a neuro-
psychological test battery including tests for different cognitive
skills would have given a more complete picture of cognitive
performance, but the PASAT does capture the aspects most
commonly affected in MS, that is, processing speed and
memory.6 Performance in the PASAT is prone to practice
effects.6 Nevertheless, the tests administered before month 6 in
BENEFIT were not used in this study. Instead, we used the
scores from tests administered thereafter (numerous test
administrations before the main outcome, PASAT at year 11)
to exclude influences of initial and thus large practice effects on
the PASAT performance.35 Any practice effect is further
unlikely to fully explain our findings, as the extent of the
practice effect is probably not related to the exposures unless
these truly have an effect. Like every cognitive test, PASAT
scores do not convey how the patient is managing cognitive
tasks in real life.6 Furthermore, ceiling effects might have
masked small PASAT changes among high-scoring individuals
who experienced a decline in functioning although still scoring
high,35 but we addressed this issue by examining performance
below a specific threshold to capture individuals whoweremost
affected in this study population. Also, the association between
25(OH)D and NfL levels was modest and at the limit of sta-
tistical significance. These associations, however, were most
likely attenuated by the long lag between the last assessment of
25(OH)D (24 months) and NfL measurement (11 years),
which was introduced to minimize the possibility of reverse
causation.
In summary, lower vitamin D levels and smoking after clinical
onset predicted worse long-term cognitive function and neu-
ronal integrity in patients with MS. These results suggest that
correcting vitaminD insufficiency and abstaining from cigarette
smoking after clinical MS onset might protect long-term cog-
nitive function and CNS integrity.
Study funding
This study was supported by grants from the National In-
stitute of Neurological Disease and Stroke (NS071082, PI Dr.
Ascherio) and the National Multiple Sclerosis Society (RG
4296A4/2, PI Dr. Ascherio). The BENEFIT trial and the
Table 4 Serum 25-hydroxyvitamin D (25(OH)D), cotinine, and EBNA-1 antibody levels and long-term neuroaxonal injury as
measured by serum NfL concentrations in patients with CIS (continued)
No.
NfL level 11 years after CIS




1 46 Ref. Ref.
2 51 −9% (−26 to +13%) −8% (−25 to +14%)
3 50 0% (−19 to +23%) −1% (−19 to +23%)
4 49 +6% (−14 to +30%) +8% (−12 to +34%)
ptrend 0.57 0.45
Abbreviations: CI = confidence interval; CIS = clinically isolated syndrome; EBNA-1 = Epstein-Barr virus nuclear antigen 1; IgG = immunoglobulin G; NfL =
neurofilament light chain.
a NfL levels were log transformed to improve normality. Linear regression coefficients, reflecting changes on a log scale, were back transformed to reflect
changes on a multiplicative scale and reported as % difference in median NfL levels between the exposure and the reference group. Confidence intervals
including 0% difference are not statistically significant using a probability cutoff of 0.05.
b Adjusted categorically for baseline age (18–22, 23–27, 28–32, 33–37, 38–42, and >43 years) and sex.
c Apart frombaseline age and sex, also adjusted for treatment allocation at baseline (interferon-beta yes-no),multifocal symptomonset (yes-no), T2-weighted
MRI lesions at baseline (categorically: 2–4, 5–8, and ≥9), body mass index at baseline (continuously), and treatment with steroids during first attack (yes-no).
d Probability value for linear trend across the medians within the categories.
e Levels of serum cotinine, a biomarker of current/recent tobacco use, at baseline and at months 6, 12, and 24 used to classify nonsmokers (all measures <10
ng/mL), smokers (>25 ng/mL), and heavy smokers (>193 ng/mL). Last available level carried forward for missing levels.
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